Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

In the past few months, the Shoklo Malaria Research Unit (SMRU) has begun a campaign to make pregnant Karen women and their husbands aware of the importance of pre-conceptual folate to prevent neural tube defects in newborns.

Meeting with local people

In the past few months, the Shoklo Malaria Research Unit (SMRU) has begun a campaign to make pregnant Karen women and their husbands aware of the importance of pre-conceptual folate to prevent neural tube defects (NTD) in newborns. NTDs are a severe problem in the Thai-Myanmar border areas served by SMRU, with 12 NTD babies per 10,000 births – nearly 10 times higher than in the USA (1.1 per 10,000) and over five times higher than a recent survey from southern Thailand (1.88 per 10,000 births).

To raise awareness among border communities, Andrew Stevens (left in top photo), a student at SMRU, has worked for the past three months with Eh Toe Toe and Beh Blue Do, public health interns with the Karen Refugee Committee Education Entity (KRCEE). Supported by a Government of Australia ASIABound short-term mobility grant, their community wide campaign has reached border-area women of childbearing age and their spouses using surveys, focus groups, community consultations and community based organisation (CBO) workshops.

Folic acid is a B-vitamin essential for proper cell growth and development of the embryo. Although essential in tissue formation, there was little awareness of its benefits and role in preventing NTDs among border area populations and local health workers, with only one quarter of SMRU health workers aware of its benefits.

Involving all parts of the community and getting local NGOs and CBOs to include pre-conceptual folate messaging in their work are essential to making the project effective and sustainable, and in getting the folic acid message to pregnant women and their husbands. 

 “The workshops with CBOs were humbling. Once participants understood the problem they were very willing to consider the best ways to disseminate the messaging to the community,” said Dr Rose McGready, SMRU Deputy Director. “The other unexpected response was from the men at outpatients who wanted to take more than one flyer for distribution. They really wanted to help get the word out on folates.”

- Text and pictures by Andrew Steven, Suphak Nosten and Rose McGready

Similar stories

World’s largest clinical trial for COVID-19 treatments expands internationally

OCGHR Research

The Randomised Evaluation of COVID-19 Therapy (RECOVERY) Trial, the world’s largest clinical trial for COVID-19 treatments, has now expanded internationally with Indonesia and Nepal among the first countries to join. The first patients have been recruited to RECOVERY International.

Tocilizumab reduces deaths in patients hospitalised with COVID-19

OCGHR Research

The Randomised Evaluation of COVID-19 Therapy (RECOVERY) trial has demonstrated that tocilizumab, an anti-inflammatory treatment, reduces the risk of death when given to hospitalised patients with severe COVID-19. The study also showed that tocilizumab shortens the time until patients are successfully discharged from hospital and reduces the need for a mechanical ventilator.

Evidence supports WHO recommendation for primaquine combined with ACTs to block Plasmodium falciparum transmission

OCGHR Publication Research

Evidence from a new study, initiated by the Primaquine Roll Out Group and conducted at WWARN, supports the World Health Organization (WHO) recommendation for use of 0.25mg/kg dose of primaquine (PQ) combined with artemisinin-based combination therapies (ACT) to block Plasmodium falciparum transmission.

Baricitinib to be investigated as a possible treatment for COVID-19 in the RECOVERY trial

OCGHR Research

Baricitinib – an anti-inflammatory treatment for rheumatoid arthritis– is being investigated in the RECOVERY trial, the world’s largest clinical trial of treatments for patients hospitalised with COVID-19, taking place in 177 hospital sites across the UK and with over 33,000 patients recruited so far. As an anti-inflammatory, baricitinib may block the signalling activity of cytokine molecules which contribute to the hyper-inflammatory state seen in severe COVID-19. It is thought that baricitinib may act also have some anti-viral activity. The other treatments currently being investigated in the RECOVERY trial are Regeneron’s antibody cocktail, Aspirin and Colchicine.

Indonesia’s decision to prioritise COVID-19 vaccination to citizens aged 18-59 years old questionable

EOCRU MORU OUCRU

The Indonesian government policy to exclude the elderly in the first phase of the COVID-19 vaccination program could hinder the vaccine’s impact in lowering mortality rates. COVID-19 mortality rates in Indonesia, the highest in Southeast Asia, are dominated by those in the 60 years and above age bracket. In this article published in The Conversation, Kartika Saraswati and fellow DPhil students elaborate how, by prioritising vaccination for elderly, Indonesia may optimally reduce the hospital burden and COVID-19 deaths amidst a limited vaccine supply during the first vaccination phase.

RECOVERY trial closes recruitment to convalescent plasma treatment for patients hospitalised with COVID-19

OCGHR Research

Convalescent plasma has been widely used as a treatment for COVID-19 but to date there has been no convincing evidence of the effect of convalescent plasma on clinical outcomes in patients admitted to hospital with COVID-19. Recruitment to the convalescent plasma arm of the RECOVERY trial has now closed. The preliminary analysis based on 1873 reported deaths among 10,406 randomised patients shows no significant difference in the primary endpoint of 28-day mortality. Recruitment to all other treatment arms – tocilizumab, aspirin, colchicine, and Regeneron’s antibody cocktail – continues as planned.